We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

12 hedge funds and large institutions have $1.02M invested in Benitec Biopharma in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

158% more capital invested

Capital invested by funds: $395K → $1.02M (+$625K)

100% more funds holding

Funds holding: 6 → 12 (+6)

0.12% more ownership

Funds ownership: 0.33% → 0.45% (+0.12%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
12
Holders Change
+6
Holders Change %
+100%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$316K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$194K
3
Two Sigma Investments
Two Sigma Investments
New York
+$167K
4
Renaissance Technologies
Renaissance Technologies
New York
+$148K
5
VF
Virtu Financial
New York
+$55.9K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$75K
2
Morgan Stanley
Morgan Stanley
New York
-$63.7K

BNTC Hedge Fund Activity: Q4 2020 in Review

12 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2020, worth a combined $1.02M — up 158% from $395K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BNTC positions and 1 closed out — a net gain of 6 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $316K. The largest seller was Sabby Management, exiting entirely with an estimated $75K sold.

  • 12 institutional investors held Benitec Biopharma (BNTC) as of Q4 2020, up from 6 in Q3 2020.
  • Funds reported $1.02M of Benitec Biopharma stock for Q4 2020, up 158% quarter-over-quarter.
  • 7 funds opened new Benitec Biopharma positions in Q4 2020 and 1 closed out, a net change of +6 holders.
  • The largest Benitec Biopharma buyer in Q4 2020 was Hudson Bay Capital Management, an estimated $316K added.
  • The largest Benitec Biopharma seller in Q4 2020 was Sabby Management, an estimated $75K sold.

Based on aggregated 13F filings for Q4 2020.